Wuzhou Zhongheng Invests $52 Million in Israel's Oramed Pharma

Wuzhou Zhongheng Group paid $52 million for a 10% stake in Oramed Pharma and China rights to its two diabetes treatments. Oramed, based in Israel, develops oral versions of injected protein drugs. Details of the deal were not disclosed. In December 2014, Zhongheng invested $5 million in Oramed for a 7% stake in the company, which suggests the China rights to the diabetes treatments are worth over $40 million. Recently, Oramed announced plans to begin a US Phase IIb trial of its oral insulin product. More details.... Stock Symbols: (SHA: 600252)   (NSDQ: ORMP) Share this with colleagues: // //